Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceuticals development and commercialisation.
Blue Earth Diagnostics is funded by Syncona LLP, a subsidiary of the Wellcome Trust, the second largest philanthropic, not-for-profit healthcare foundation in the world.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
Who we work with
See how you can join the team
Where we are going to be
BURLINGTON, Mass. and OXFORD, UK, September 6, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the upcoming oral presentation of initial results from the FALCON...
Read More ›BURLINGTON, Mass. and OXFORD, UK – Aug. 30, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company, announced today that it has been named as a finalist as...
Read More ›Oxford, UK – August 11, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that it has been shortlisted as a finalist in the 2017 OBN...
Read More ›Oxford, UK –July 27, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company and M2i, a manufacturer of Positron Emission Tomography (PET) imaging agents, today announced that they...
Read More ›